<!doctype html><html lang=zh-tw><head><meta charset=utf-8><meta name=description content="at: [[inbox]]
Rheumatology - Spondyloarthritis - Fast Facts | NEJM Resident 360 Spondyloarthritis is an inflammatory arthritis characterized by the following features:"><meta property="og:title" content><meta property="og:description" content><meta property="og:type" content="website"><meta property="og:url" content><meta property="og:image" content="https://og-ph6wrfvo1-htlin222.vercel.app/api/blog?templateTitle=Rheumatology - Spondyloarthritis - Fast Facts | NEJM Resident 360"><title>Rheumatology - Spondyloarthritis - Fast Facts | NEJM Resident 360</title><meta name=viewport content="width=device-width,initial-scale=1"><link rel=alternate type=application/rss+xml href=https://www.physician.tw//feed.xml title><link rel="shortcut icon" type=image/png href=https://www.physician.tw//icon.png><link href=https://www.physician.tw/styles.720e2c4835986a3891d6eef3a55faa22.min.css rel=stylesheet><link href=https://www.physician.tw/styles/_light_syntax.86a48a52faebeaaf42158b72922b1c90.min.css rel=stylesheet id=theme-link><script src=https://www.physician.tw/js/darkmode.dfadb738e747a87e78c7144d7267f1bc.min.js></script>
<script src=https://www.physician.tw/js/util.6f22941e242efae60fd84e7c32e874fa.min.js></script>
<link rel=preload href=https://cdn.jsdelivr.net/npm/katex@0.15.1/dist/katex.min.css as=style onload='this.onload=null,this.rel="stylesheet"' integrity=sha384-R4558gYOUz8mP9YWpZJjofhk+zx0AS11p36HnD2ZKj/6JR5z27gSSULCNHIRReVs crossorigin=anonymous><script defer src=https://cdn.jsdelivr.net/npm/katex@0.15.1/dist/katex.min.js integrity=sha384-z1fJDqw8ZApjGO3/unPWUPsIymfsJmyrDVWC8Tv/a1HeOtGmkwNd/7xUS0Xcnvsx crossorigin=anonymous></script>
<script defer src=https://cdn.jsdelivr.net/npm/katex@0.15.1/dist/contrib/auto-render.min.js integrity=sha384-+XBljXPPiv+OzfbB3cVmLHf4hdUFHlWNZN5spNQ7rmHTXpd7WvJum6fIACpNNfIR crossorigin=anonymous></script>
<script defer src=https://cdn.jsdelivr.net/npm/katex@0.16.2/dist/contrib/copy-tex.min.js integrity=sha384-ww/583aHhxWkz5DEVn6OKtNiIaLi2iBRNZXfJRiY1Ai7tnJ9UXpEsyvOITVpTl4A crossorigin=anonymous></script>
<script async src=https://unpkg.com/@floating-ui/core@0.7.3></script>
<script async src=https://unpkg.com/@floating-ui/dom@0.5.4></script>
<script async src=https://www.physician.tw/js/popover.f03552ccb84d99ca615d1cfb9abde59e.min.js></script>
<script defer src=https://www.physician.tw/js/code-title.ce4a43f09239a9efb48fee342e8ef2df.min.js></script>
<script defer src=https://www.physician.tw/js/clipboard.2913da76d3cb21c5deaa4bae7da38c9f.min.js></script>
<script defer src=https://www.physician.tw/js/callouts.7723cac461d613d118ee8bb8216b9838.min.js></script>
<script>const SEARCH_ENABLED=!1,LATEX_ENABLED=!0,PRODUCTION=!0,BASE_URL="https://www.physician.tw/",fetchData=Promise.all([fetch("https://www.physician.tw/indices/linkIndex.90107d0b93aa1a7b5d61f28d120852cd.min.json").then(e=>e.json()).then(e=>({index:e.index,links:e.links})),fetch("https://www.physician.tw/indices/contentIndex.b5965c1278f76865776954bf25e78551.min.json").then(e=>e.json())]).then(([{index:e,links:t},n])=>({index:e,links:t,content:n})),render=()=>{const e=new URL(BASE_URL),t=e.pathname,n=window.location.pathname,s=t==n;addCopyButtons(),addTitleToCodeBlocks(),addCollapsibleCallouts(),initPopover("https://www.physician.tw",!0);const o=document.getElementById("footer");if(o){const e=document.getElementById("graph-container");if(!e)return requestAnimationFrame(render);e.textContent="";const t=s&&!1;drawGraph("https://www.physician.tw",t,[{"/moc":"#4388cc"}],t?{centerForce:1,depth:-1,enableDrag:!0,enableLegend:!1,enableZoom:!0,fontSize:.5,linkDistance:1,opacityScale:3,repelForce:1,scale:1.4}:{centerForce:1,depth:1,enableDrag:!0,enableLegend:!1,enableZoom:!0,fontSize:.6,linkDistance:1,opacityScale:3,repelForce:2,scale:1.2})}},init=(e=document)=>{addCopyButtons(),addTitleToCodeBlocks(),renderMathInElement(e.body,{delimiters:[{left:"$$",right:"$$",display:!0},{left:"$",right:"$",display:!1}],macros:{'’':"'"},throwOnError:!1})}</script><script type=module>
    import { attachSPARouting } from "https:\/\/www.physician.tw\/js\/router.9d4974281069e9ebb189f642ae1e3ca2.min.js"
    attachSPARouting(init, render)
  </script></head><body><div id=search-container><div id=search-space><input autocomplete=off id=search-bar name=search type=text aria-label=搜尋 placeholder="請輸入像是：hypertension 之類的來看沒有沒什麼有趣的🎳"><div id=results-container></div></div></div><script src=https://cdn.jsdelivr.net/npm/flexsearch@0.7.21/dist/flexsearch.bundle.js integrity="sha256-i3A0NZGkhsKjVMzFxv3ksk0DZh3aXqu0l49Bbh0MdjE=" crossorigin=anonymous defer></script>
<script defer src=https://www.physician.tw/js/full-text-search.e6e2e0c213187ca0c703d6e2c7a77fcd.min.js></script><div class=singlePage><header><h1 id=page-title><a href=https://www.physician.tw/>蜥蜴花園🦎🌱🪴🌲</a></h1><div class=spacer></div><div id=search-icon><p>搜尋</p><svg tabindex="0" aria-labelledby="title desc" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 19.9 19.7"><title id="title">搜尋圖示</title><desc id="desc">打開搜尋圖標</desc><g class="search-path" fill="none"><path stroke-linecap="square" d="M18.5 18.3l-5.4-5.4"/><circle cx="8" cy="8" r="7"/></g></svg></div><div class=darkmode><input class=toggle id=darkmode-toggle type=checkbox tabindex=-1>
<label id=toggle-label-light for=darkmode-toggle tabindex=-1><svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" id="dayIcon" viewBox="0 0 35 35" style="enable-background:new 0 0 35 35"><title>明亮模式</title><path d="M6 17.5C6 16.672 5.328 16 4.5 16h-3C.672 16 0 16.672.0 17.5S.672 19 1.5 19h3C5.328 19 6 18.328 6 17.5zM7.5 26c-.414.0-.789.168-1.061.439l-2 2C4.168 28.711 4 29.086 4 29.5 4 30.328 4.671 31 5.5 31c.414.0.789-.168 1.06-.44l2-2C8.832 28.289 9 27.914 9 27.5 9 26.672 8.329 26 7.5 26zm10-20C18.329 6 19 5.328 19 4.5v-3C19 .672 18.329.0 17.5.0S16 .672 16 1.5v3C16 5.328 16.671 6 17.5 6zm10 3c.414.0.789-.168 1.06-.439l2-2C30.832 6.289 31 5.914 31 5.5 31 4.672 30.329 4 29.5 4c-.414.0-.789.168-1.061.44l-2 2C26.168 6.711 26 7.086 26 7.5 26 8.328 26.671 9 27.5 9zM6.439 8.561C6.711 8.832 7.086 9 7.5 9 8.328 9 9 8.328 9 7.5c0-.414-.168-.789-.439-1.061l-2-2C6.289 4.168 5.914 4 5.5 4 4.672 4 4 4.672 4 5.5c0 .414.168.789.439 1.06l2 2.001zM33.5 16h-3c-.828.0-1.5.672-1.5 1.5s.672 1.5 1.5 1.5h3c.828.0 1.5-.672 1.5-1.5S34.328 16 33.5 16zM28.561 26.439C28.289 26.168 27.914 26 27.5 26c-.828.0-1.5.672-1.5 1.5.0.414.168.789.439 1.06l2 2C28.711 30.832 29.086 31 29.5 31c.828.0 1.5-.672 1.5-1.5.0-.414-.168-.789-.439-1.061l-2-2zM17.5 29c-.829.0-1.5.672-1.5 1.5v3c0 .828.671 1.5 1.5 1.5s1.5-.672 1.5-1.5v-3C19 29.672 18.329 29 17.5 29zm0-22C11.71 7 7 11.71 7 17.5S11.71 28 17.5 28 28 23.29 28 17.5 23.29 7 17.5 7zm0 18c-4.136.0-7.5-3.364-7.5-7.5s3.364-7.5 7.5-7.5 7.5 3.364 7.5 7.5S21.636 25 17.5 25z"/></svg></label><label id=toggle-label-dark for=darkmode-toggle tabindex=-1><svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" id="nightIcon" viewBox="0 0 100 100" style="enable-background='new 0 0 100 100'"><title>黑暗模式</title><path d="M96.76 66.458c-.853-.852-2.15-1.064-3.23-.534-6.063 2.991-12.858 4.571-19.655 4.571C62.022 70.495 50.88 65.88 42.5 57.5 29.043 44.043 25.658 23.536 34.076 6.47c.532-1.08.318-2.379-.534-3.23-.851-.852-2.15-1.064-3.23-.534-4.918 2.427-9.375 5.619-13.246 9.491-9.447 9.447-14.65 22.008-14.65 35.369.0 13.36 5.203 25.921 14.65 35.368s22.008 14.65 35.368 14.65c13.361.0 25.921-5.203 35.369-14.65 3.872-3.871 7.064-8.328 9.491-13.246C97.826 68.608 97.611 67.309 96.76 66.458z"/></svg></label></div></header><article><h1>Rheumatology - Spondyloarthritis - Fast Facts | NEJM Resident 360</h1><p class=meta>最後更新於
Feb 23, 2023
<a href=https://github.com/htlin222/garden/tree/hugo/content/Rheumatology%20-%20Spondyloarthritis%20-%20Fast%20Facts%20%20NEJM%20Resident%20360.md rel=noopener>🪚 編輯原始文件</a></p><ul class=tags></ul><p>at: <a class="internal-link broken">inbox</a></p><a href=#rheumatology---spondyloarthritis---fast-facts--nejm-resident-360><h1 id=rheumatology---spondyloarthritis---fast-facts--nejm-resident-360><span class=hanchor arialabel=Anchor># </span>Rheumatology - Spondyloarthritis - Fast Facts | NEJM Resident 360</h1></a><p>Spondyloarthritis is an inflammatory arthritis characterized by the following features:</p><ul><li><p>peripheral inflammatory arthritis (particularly an asymmetric oligoarthritis of large joints)</p></li><li><p>enthesitis (inflammation of tendon insertion points)</p></li><li><p>dactylitis (diffuse swelling of a digit due to diffuse tendon and joint inflammation) </p></li><li><p>uveitis</p></li><li><p>inflammatory back pain (axial arthritis)</p></li></ul><p>There are seven spondyloarthritides:</p><ul><li><p>Psoriatic Arthritis (PsA)</p></li><li><p>Ankylosing Spondylitis (AS)</p></li><li><p>Nonradiographic Axial Spondyloarthropathy (nrAxSpA)</p></li><li><p>Inflammatory Bowel Disease (IBD)-Related Arthritis</p></li><li><p>Reactive Arthritis</p></li><li><p>Peripheral Spondyloarthritis (not covered in this guide)</p></li><li><p>Juvenile Spondyloarthritis (not covered in this guide)</p></li></ul><p>“Undifferentiated spondyloarthritis” is the term used for the rare cases when it is not possible to identify which type of spondyloarthritis a patient has. However, in general, the forms of spondyloarthritides can be differentiated on the basis of their clinical features as outlined in the table below:</p><a href=#clinical-features-of-various-forms-of-spondyloarthritis><h3 id=clinical-features-of-various-forms-of-spondyloarthritis><span class=hanchor arialabel=Anchor># </span>Clinical Features of Various Forms of Spondyloarthritis</h3></a><p><strong>(Source: Psoriatic Arthritis. N Engl J Med 2017.)</strong></p><a href=#psoriatic-arthritis><h2 id=psoriatic-arthritis><span class=hanchor arialabel=Anchor># </span>Psoriatic Arthritis</h2></a><p>Psoriatic arthritis (PsA) affects up to 30% of people with psoriasis. In nearly every case, there is a personal or family history of psoriasis; in some cases, the arthritis may precede the skin or nail changes associated with psoriasis. Psoriatic arthritis is characterized by the following features:</p><ul><li><p>asymmetric oligoarthritis of large joints</p></li><li><p>symmetrical polyarthritis of proximal small joints (mimicking rheumatoid arthritis)</p></li><li><p>distal interphalangeal joint arthritis (typically seen with nail psoriasis)</p></li><li><p>axial spondyloarthritis</p></li><li><p>arthritis mutilans (an aggressive, deforming arthritis with typical appearances of pencil-in-cup deformity on plain radiographs and eventually opera-glass deformity of the hands)</p></li></ul><a href=#clinical-features-of-psoriatic-arthritis><h3 id=clinical-features-of-psoriatic-arthritis><span class=hanchor arialabel=Anchor># </span>Clinical Features of Psoriatic Arthritis</h3></a><p><strong>Panel A shows the distal subtype of psoriatic arthritis, with adjacent onycholysis. Panel B shows the oligoarticular subtype. Panel C shows the polyarticular subtype. Panel D show arthritis mutilans, with telescoping of digits and asymmetric and differential involvement of adjacent digits. Panel E shows the spondylitis subtype. Panel F shows enthesitis of the Achilles’ tendon (arrow).<br>(Source: Psoriatic Arthritis. N Engl J Med 2017.)</strong></p><a href=#diagnosis><h3 id=diagnosis><span class=hanchor arialabel=Anchor># </span>Diagnosis</h3></a><p>PsA is diagnosed clinically with supporting information from investigations. The common features of spondylarthritis are almost always present to some extent, with dactylitis and enthesitis frequently accompanying the arthritis. There is almost always a personal or family history of psoriasis, often including nail involvement.</p><p>In contrast with rheumatoid arthritis, <strong>PsA is not associated with rheumatoid factor (RF</strong> ) <strong>or anti-CCP antibodies</strong>; the detection of these antibodies in peripheral blood should raise the possibility of an alternative diagnosis, such as rheumatoid arthritis. For the purposes of clinical research, the Classification Criteria for Psoriatic Arthritis are commonly used and can be useful to clinicians.</p><a href=#the-caspar-criteria><h3 id=the-caspar-criteria><span class=hanchor arialabel=Anchor># </span>The CASPAR Criteria*</h3></a><table><tbody><tr><td>To meet the CASPAR (ClASsification criteria for Psoriatic ARthritis) criteria, a patient must have inflammatory articular disease (joint, spine, or entheseal) with ≥3 points from the following five categories:</td></tr><tr><td>1. Evidence of current psoriasis, a personal history of psoriasis, or a family history of psoriasis†</td></tr><tr><td>2. Typical psoriatic nail dystrophy including onycholysis, pitting, and hyperkeratosis observed on current physical examination</td></tr><tr><td>3. A negative test result for the presence of rheumatoid factor by any method except latex</td></tr><tr><td>4. Either current dactylitis, defined as swelling of an entire digit, or a history of dactylitis recorded by a rheumatologist</td></tr><tr><td>5. Radiographic evidence of juxta-articular new bone formation, appearing as ill‐defined ossification near joint margins (but excluding osteophyte formation) on plain radiographs of the hand or foot</td></tr></tbody></table><a href=#-the-caspar-criteria-have-specificity-of-987-and-sensitivity-of-914-for-psoriatic-arthritis-among-individuals-with-inflammatory-musculoskeletal-disease-peripheral-arthritis-axial-disease-or-enthesitis><h6 id=-the-caspar-criteria-have-specificity-of-987-and-sensitivity-of-914-for-psoriatic-arthritis-among-individuals-with-inflammatory-musculoskeletal-disease-peripheral-arthritis-axial-disease-or-enthesitis><span class=hanchor arialabel=Anchor># </span>* The CASPAR criteria have specificity of 98.7% and sensitivity of 91.4% **for psoriatic arthritis among individuals with inflammatory musculoskeletal disease (peripheral arthritis, axial disease, or enthesitis).</h6></a><p>**† Current psoriasis is assigned a score of 2; all other features are assigned a score of 1.<br>(Reference: Classification Criteria for Psoriatic Arthritis: Development of New Criteria from a Large International Study.  Arthritis Rheumatol 2006.)</p><a href=#imaging><h3 id=imaging><span class=hanchor arialabel=Anchor># </span>Imaging</h3></a><p>Plain radiographs: The typical abnormality seen on plain radiographs is a combination of bone loss (with eccentric erosions) and new bone formation (with ankyloses, enthesophytes, syndesmophytes, and periostitis). Other features that may be seen on plain radiograph include:</p><ul><li><p>bone formation at the site of periarticular structural insertions (such as tendons)</p></li><li><p>periostitis at the lateral margins of the interphalangeal joints as a fluffy-appearing opacification</p></li><li><p>pencil-in-cup deformities, seen with the arthritis mutilans presentation of PsA, characterized by tapering of one phalanx and central destruction of the opposite phalanx</p></li><li><p>enthesitis, seen as a calcification in line with the tendon insertion on the bone</p></li><li><p>dactylitis, observed as a swelling of soft tissue of the digit</p></li><li><p>axial involvement, observed, when it occurs, asymmetrically in the sacroiliac joints</p></li></ul><a href=#treatment><h3 id=treatment><span class=hanchor arialabel=Anchor># </span>Treatment</h3></a><p>The optimal treatment of psoriatic arthritis depends on the severity of the disease as follows:</p><ul><li><p>Mild disease: Nonsteroidal anti-inflammatory drugs (NSAIDs) and acetaminophen may be all that is required.</p></li><li><p>Moderate disease: Disease-modifying antirheumatic drugs (DMARDs) are often required, although they tend to be more effective for treatment of peripheral arthritis than spondylitis. Historically, weekly oral methotrexate has been used, though evidence for its benefits has not been clearly demonstrated in the published literature. Other DMARDs often used include leflunomide and sulfasalazine. In some cases of mild-to-moderate disease, apremilast (a phosphodiesterase type 4 inhibitor) may also be used.</p></li><li><p>Severe disease: Treatment involves biologic DMARDs (bDMARDs), including monoclonal antibodies against tumor necrosis factor-alpha (TNF-alpha inhibitor; etanercept, adalimumab, golimumab, infliximab, certolizumab pegol), interleukin-17 (secukinumab, ixekizumab), interleukin-12/23 (ustekinumab), interleukin 23 (guselkumab), T-cell costimulation (abatacept), or small-molecule inhibitors, such as Janus kinase (JAK) inhibitors (tofacitinib).</p></li></ul><p>Glucocorticoids are effective at treating inflammatory arthritis at all stages but tend to be reserved due to possible glucocorticoid-related adverse effects and because cessation of glucocorticoids can trigger a severe flare of psoriasis. When pustular psoriasis or erythroderma is present, glucocorticoids should be avoided. Intra-articular glucocorticoid injection therapy can be highly effective.</p><p>Skin disease will respond to most of the treatments listed above, but dermatologists may also utilize ultraviolet light therapy or cyclosporine in addition to topical therapies. Such treatments have minimal or no effect on arthritis.</p><a href=#ankylosing-spondylitis><h2 id=ankylosing-spondylitis><span class=hanchor arialabel=Anchor># </span>Ankylosing Spondylitis</h2></a><p>Ankylosing spondylitis (AS) is characterized by inflammatory lower-back pain centering on the sacroiliac joints. Symptoms suggesting sacroiliitis (rather than another cause of back pain) include prolonged morning stiffness and improvement with exercise. Over decades, the sacroiliac joints and spinal vertebrae may fuse, eventually leading to an exaggerated thoracic kyphosis and forward thrusting of the neck.</p><p>The extra-axial manifestations of spondyloarthritis can also be present, particularly peripheral arthritis and uveitis.</p><a href=#characteristics-of-inflammatory-back-pain><h3 id=characteristics-of-inflammatory-back-pain><span class=hanchor arialabel=Anchor># </span>Characteristics of Inflammatory Back Pain</h3></a><p><strong>(Source: Ankylosing Spondylitis and Axial Spondyloarthritis. N Engl J Med 2016.)</strong></p><a href=#diagnosis-1><h3 id=diagnosis-1><span class=hanchor arialabel=Anchor># </span>Diagnosis</h3></a><p>It is common for many years to pass before a diagnosis of AS is made. Usually radiograph or MRI evidence of ankylosing spondylitis is needed to confirm diagnosis.</p><p>Testing for HLA-B27 does not usually aid in the diagnostic workup, though the <em>HLA-B27</em> gene is often present in patients with AS; it is also common in the general population (8% to 10% of white patients).</p><p>A trial of NSAIDs can greatly aid in the diagnostic workup, as AS tends to improve substantially with the use of NSAIDs compared to other analgesics.</p><a href=#nonradiographic-axial-spondyloarthritis><h2 id=nonradiographic-axial-spondyloarthritis><span class=hanchor arialabel=Anchor># </span>Nonradiographic Axial Spondyloarthritis</h2></a><p>NrAxSpA can be thought of as a preradiographic stage of AS. In some patients, there are unequivocal manifestations of spondyloarthritis with inflammatory back pain, but plain radiographs do not demonstrate sacroiliitis. In such cases, MRI can help identify bone-marrow edema near the sacroiliac joints, suggesting inflammation.</p><p>Such patients are diagnosed with nrAxSpa and are treated in a similar manner to AS, with NSAIDs, physical activity, stretching, DMARDs, and bDMARDs.</p><a href=#diagnostic-algorithm-for-axial-spondyloarthritis><h3 id=diagnostic-algorithm-for-axial-spondyloarthritis><span class=hanchor arialabel=Anchor># </span>Diagnostic Algorithm for Axial Spondyloarthritis</h3></a><p><strong>(Source: Ankylosing Spondylitis and Axial Spondyloarthritis. N Engl J Med 2016.)</strong></p><a href=#treatment-1><h3 id=treatment-1><span class=hanchor arialabel=Anchor># </span>Treatment</h3></a><ul><li><p>NSAIDs are the main pharmacologic therapy for AS, providing at least significant symptomatic improvement.</p></li><li><p>Stretching and physical activity are the main nonpharmacologic treatments for AS. In addition to providing analgesia, stretching in particular will help maintain flexibility of the spine for as long as possible.</p></li><li><p>Biologic DMARDs — TNF-alpha inhibitors are highly effective, particularly when there is impairment of daily function despite the combination of NSAIDs, physical activity, and stretching.</p></li><li><p>DMARDs — Methotrexate or sulfasalazine might be effective in the setting of peripheral arthritis; they do not provide any substantial benefit in the management of inflammatory back pain.</p></li></ul><a href=#inflammatory-bowel-disease-ibd-related-arthritis><h2 id=inflammatory-bowel-disease-ibd-related-arthritis><span class=hanchor arialabel=Anchor># </span>Inflammatory Bowel Disease (IBD)-Related Arthritis</h2></a><a href=#diagnosis-2><h3 id=diagnosis-2><span class=hanchor arialabel=Anchor># </span>Diagnosis</h3></a><p>IBD-related arthritis is diagnosed when the features of spondyloarthritis are associated with IBD. Features of IBD include hematochezia, diarrhea, abdominal pain, and recurrent aphthous ulcers; confirmation with upper/lower endoscopy and tissue biopsy is usually required, along with specialist assessment by a gastroenterologist. (For more information on IBD, see Inflammatory Bowel Disease in the Gastroenterology rotation guide.)</p><p>Peripheral, axial, and extra-articular manifestations of spondyloarthritis might be present. Some patients with IBD-related arthritis will have symptoms that coincide with an increase in IBD activity. In these cases, controlling the IBD will lead to improvements in the arthritis. For the rest, the spondyloarthritis features may persist independently of the IBD activity.</p><a href=#treatment-2><h3 id=treatment-2><span class=hanchor arialabel=Anchor># </span>Treatment</h3></a><ul><li><p>Optimize control of IBD; this may include biologic treatments (such as TNF-alpha inhibitors) that may be particularly effective for inflammatory arthritis or spondylitis.</p></li><li><p>Consider NSAIDs, though they may worsen IBD activity and/or increase bleeding risk.</p></li><li><p>For peripheral arthritis, consider DMARDs such as methotrexate or sulfasalazine.</p></li><li><p>For oligoarthritis, targeted intra-articular steroid injections can be beneficial.</p></li><li><p>For uveitis, treatment of acute flares is necessary. If uveitis is recurrent, TNF inhibitors may be appropriate.</p></li></ul><a href=#reactive-arthritis><h2 id=reactive-arthritis><span class=hanchor arialabel=Anchor># </span>Reactive Arthritis</h2></a><p>Reactive arthritis is characterized by oligoarthritis occurring with uveitis, conjunctivitis, or urethritis.</p><p>In most cases there is a recent (within 3 months) history of a gastrointestinal or genitourinary infection. Typical spondyloarthritis features can be seen, particularly an asymmetric oligoarthritis. Sacroiliitis can occur but is usually asymmetric (in contrast to the symmetrical inflammation of AS).</p><p>The prognosis is good, with resolution expected within 3 to 6 months. On occasion the arthritis persists for longer than 12 months.</p><a href=#diagnosis-3><h3 id=diagnosis-3><span class=hanchor arialabel=Anchor># </span>Diagnosis</h3></a><p>The diagnosis is confirmed by identifying a causative microorganism from stool samples (such as Salmonella species) or urine samples (especially <em>Chlamydia trachomatis</em>), in conjunction with a compatible disease presentation of spondyloarthritis.</p><p>Causative organisms include:</p><ul><li><p><em>Chlamydia spp.</em> (especially <em>C. trachomatis</em>)</p></li><li><p><em>Campylobacter jejuni</em></p></li><li><p><em>Yersinia enterocolitica</em></p></li><li><p><em>Shigella spp.</em> (especially <em>S. flexeneri</em>)</p></li><li><p><em>Salmonella spp.</em></p></li></ul><a href=#treatment-3><h3 id=treatment-3><span class=hanchor arialabel=Anchor># </span>Treatment</h3></a><p>In mild cases, NSAIDs may suffice until the features resolve. In more severe cases, glucocorticoids are required (either intra-articular or systemic) as well as DMARDs. Sulfasalazine is often used in the first instance, or weekly oral methotrexate, though their efficacy is variable.</p><p><a class="internal-link broken">inbox</a></p></article><hr><div class=page-end id=footer><div class=backlinks-container><h3>↩️ 反向連結</h3><ul class=backlinks><li><a href=/all-list-of-resident360/ data-ctx="Rheumatology - Spondyloarthritis - Fast Facts  NEJM Resident 360" data-src=/all-list-of-resident360 class=internal-link>all list of resident360</a></li><li><a href=/rheumatology/ data-ctx="Rheumatology - Spondyloarthritis - Fast Facts  NEJM Resident 360" data-src=/rheumatology class=internal-link>rheumatology</a></li></ul></div><div><script async src=https://cdn.jsdelivr.net/npm/d3@6.7.0/dist/d3.min.js integrity="sha256-+7jaYCp29O1JusNWHaYtgUn6EhuP0VaFuswhNV06MyI=" crossorigin=anonymous></script><h3>🤯互動圖</h3><div id=graph-container></div><style>:root{--g-node:var(--secondary);--g-node-active:var(--primary);--g-node-inactive:var(--visited);--g-link:var(--outlinegray);--g-link-active:#5a7282}</style><script src=https://www.physician.tw/js/graph.2d9e48dbe7ea47c0ef1c58296ce14448.js></script></div></div><div><div id=disqus_thread></div><script type=application/javascript>window.disqus_config=function(){},function(){if(["localhost","127.0.0.1"].indexOf(window.location.hostname)!=-1){document.getElementById("disqus_thread").innerHTML="Disqus comments not available by default when the website is previewed locally.";return}var t=document,e=t.createElement("script");e.async=!0,e.src="//physician.disqus.com/embed.js",e.setAttribute("data-timestamp",+new Date),(t.head||t.body).appendChild(e)}()</script><noscript>Please enable JavaScript to view the <a href=https://disqus.com/?ref_noscript>comments powered by Disqus.</a></noscript><a href=https://disqus.com class=dsq-brlink>comments powered by <span class=logo-disqus>Disqus</span></a></div><div id=contact_buttons><footer><p>本網站是由 Hsieh-Ting Lin 以❤️ 用 <a href=https://github.com/jackyzha0/quartz>Quartz</a>這個酷東西種出來🪴 , © 2023</p><ul><li><a href=https://www.physician.tw/>🏠首頁</a></li><li><a href=https://www.facebook.com/Tim.H.Lin>Facebook</a></li><li><a href=https://twitter.com/htlin222>Twitter</a></li><li><a href=https://github.com/htlin222>GitHub</a></li><li><a href=https://htlin.site>Blog</a></li><li><a href=https://medium.com/@hsieh-ting-lin>Medium</a></li></ul></footer></div></div></body></html>